The Latest Breaking News from Obesity

Recent data reveals that the eurozone economy has narrowly skirted a recession, showing lukewarm yet positive growth. With the EU and euro area expected to grow steadily over the next two years, investing in quality stocks like Novo Nordisk (NVO), SAP SE (SAP), and Shell plc (SHEL) could be beneficial.…

Hims stock rallied almost 22% over two days on enthusiasm after the FDA said it will allow compounded versions of Lilly's obesity drug.

There was a moment a couple of years ago, as weight-loss injections first erupted into popular consciousness, when it looked as though they couldn’t possibly endure. All right-thinking people were, it seemed, reflexively horrified by the suddenly rampant use and abuse of Ozempic and its compatriots by Hollywood elites. Disturbing…

Everything you need to know about ‘skinny jabs’.

The new trial aims to gather evidence of the effects of the drug tirzepatide – sold by pharmaceutical company Lily under brand name Mounjaro

Hims stock popped Monday after the FDA reportedly said it would reconsider its decision to bar compounders from selling knockoff tirzepatide.

Amgen stock dipped Monday after an analyst downgraded shares, saying the opportunity for its weight-loss drug is already baked into the stock.

Women seeking publicly funded fertility treatment in New Zealand must have a body mass index (BMI) under 32, according to clinical priority assessment criteria for access to assisted reproductive technology.

Ultra-processed foods are the latest nutritional villains, associated with several diseases of the modern world, from obesity to heart disease. However, many nutritionists question whether the term “ultra-processed” does any more than create confusion. It only considers the way food is produced, ignoring other important factors like calories and nutrients.